US Real-World Management of EGFR-Mutated Advanced NSCLC: Prescribing and Attrition Data from First-To-Second-Line Treatment

被引：5
|
作者：
Reckamp, K. [1 ]
Nieva, J. [2 ]
Taylor, A. [3 ]
Thakrar, B. [3 ]
Wong, J. [4 ]
Potter, D. [3 ]
Bakker, N. [5 ]
Rubinstein, W. [6 ]
Sun, P. [7 ]
机构：
[1] City Hope Comprehens Canc Ctr, Duarte, CA USA
[2] Univ Southern Calif, Norris Canc Ctr, Los Angeles, CA USA
[3] Astrazeneca, Global Med Affairs, Oncol Business Unit, Global Epidemiol, Cambridge, England
[4] Astrazeneca, Med Evidence & Observat Res Ctr, Global Med Affairs, Gaithersburg, MD USA
[5] Astrazeneca, Oncol Business Unit, Med, Cambridge, England
[6] Cancerlinq Llc, Amer Soc Clin Oncol, Alexandria, VA USA
[7] Astrazeneca, Med Evidence & Observat Res Ctr, Cambridge, England
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
EGFRm; NSCLC; attrition;
D O I：
10.1016/j.jtho.2019.08.820
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.01-105
引用
收藏
页码：S402 / S402
页数：1
相关论文
共 50 条
  • [1] Retrospective Analysis of Real-World Management of EGFR-Mutated Advanced NSCLC, After First-Line EGFR-TKI Treatment: US Treatment Patterns, Attrition, and Survival Data
    Nieva, Jorge
    Reckamp, Karen L.
    Potter, Danielle
    Taylor, Aliki
    Sun, Ping
    DRUGS-REAL WORLD OUTCOMES, 2022, 9 (03) : 333 - 345
  • [2] Retrospective Analysis of Real-World Management of EGFR-Mutated Advanced NSCLC, After First-Line EGFR-TKI Treatment: US Treatment Patterns, Attrition, and Survival Data
    Jorge Nieva
    Karen L. Reckamp
    Danielle Potter
    Aliki Taylor
    Ping Sun
    Drugs - Real World Outcomes, 2022, 9 : 333 - 345
  • [3] US Real-World Management of EGFR-Mutated Advanced NSCLC: Survival After First-Line EGFR-Tyrosine Kinase Inhibitor Treatment
    Nieva, J.
    Reckamp, K.
    Taylor, A.
    Thakrar, B.
    Wong, J.
    Potter, D.
    Bakker, N.
    Rubinstein, W.
    Sun, P.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S398 - S399
  • [4] Mortality among EGFR-mutated advanced NSCLC patients after frontline osimertinib treatment: A real-world, US attrition analysis
    Girard, N.
    Leighl, N.
    Ohe, Y.
    Kim, T. M.
    Demirdjian, L.
    Bourla, A. B.
    Sultan, A. Abdul
    Mahadevia, P.
    Bauml, J. M.
    Sabari, J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S51 - S52
  • [5] Real-World-Data on First-Line Therapy with Osimertinib in Patients with advanced EGFR-mutated NSCLC
    Griesinger, F.
    Nieva, J.
    Kim, Y.
    Cohen, A.
    Horvat, P.
    Lu, S.
    Taylor, A.
    Yu, N.
    Shenolikar, R.
    Shaw, S.
    PNEUMOLOGIE, 2021, 75 : S11 - S11
  • [6] Real-world effectiveness and safety of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)
    Zhou, J.
    Shen, L.
    Lv, D.
    Tang, K.
    Zhu, D.
    Zhao, Y.
    Wang, K.
    Wang, Y.
    Xing, L.
    Cui, J.
    Ding, L.
    Shi, X.
    Zheng, J.
    Zhou, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1689 - S1690
  • [7] Real-World Outcomes of Patients with Advanced EGFR-Mutated NSCLC in Canada Using AI-Extracted Data
    Moulson, Ruth
    Law, Jennifer
    Sacher, Adrian
    Liu, Geoffrey
    Shepherd, Frances
    Bradburyb, Penelope
    Eng, Lawson
    Iczkovitz, Sandra
    Abbie, Erica
    Elia-Pacitti, Julia
    Ewara, Emmanuel M.
    Mokriak, Viktoriia
    Weiss, Jessica
    Pettengell, Christopher
    Leighl, Natasha
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E12 - E13
  • [8] Real-world implementation of sequential targeted therapies for EGFR-mutated NSCLC
    Christopoulos, P.
    Volckmar, A-L.
    Bozorgmehr, F.
    Magios, N.
    Kuon, J. B.
    Kirchner, M.
    Kazdal, D.
    Endris, V.
    Bochtler, T.
    Herth, F. J. F.
    Heussel, C-P.
    Winter, H.
    Muley, T.
    Meister, M.
    Fischer, J. R.
    Rieken, S.
    Faehling, M.
    Bischoff, H.
    Stenzinger, A.
    Thomas, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [9] Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients
    Reale, Maria Lucia
    Chiari, Rita
    Tiseo, Marcello
    Vitiello, Fabiana
    Barbieri, Fausto
    Cortinovis, Diego
    Ceresoli, Giovanni Luca
    Finocchiaro, Giovanna
    Romano, Gianpiero Diego
    Piovano, Pier Luigi
    Del Conte, Alessandro
    Borra, Gloria
    Verderame, Francesco
    Scotti, Vieri
    Nonnis, Daniela
    Galetta, Domenico
    Sergi, Concetta
    Migliorino, Maria Rita
    Tonini, Giuseppe
    Cecere, Fabiana
    Berardi, Rossana
    Pino, Maria Simona
    Martelli, Olga
    Gelibter, Alain
    Carta, Annamaria
    Vattemi, Emanuela
    Pagano, Maria
    Zullo, Alessandro
    Ferrari, Silvia
    Rossi, Antonio
    Novello, Silvia
    LUNG CANCER, 2020, 140 : 71 - 79
  • [10] Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC
    Vergnenegre, Alain
    Massuti, Bartomeu
    de Marinis, Filippo
    Carcereny, Enric
    Felip, Enriqueta
    Do, Pascal
    Miguel Sanchez, Jose
    Paz-Arez, Luis
    Chouaid, Christos
    Rosell, Rafael
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (06) : 801 - 807
12345